Q/C Technologies, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Q/C Technologies, Inc. (QCLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 50 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-12
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 0.00 shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 50.00 shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 2.38K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was -4.04M shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 2.46K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 139.24K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 40.00 shares, a 66.39% decline from fiscal 2019.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2019 was 119.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 50.00 shares 10-Q · filed 2026-08-12 | 2.43K shares derived: sum of 3 quarters · filed 2026-08-12 | |
| 2026-03-31 | 50.00 shares 10-Q · filed 2026-05-15 | 2.43K shares derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-12-31 | 2.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | 2.46K shares 10-K · filed 2026-04-15 | ||
| 2025-09-30 | 78.00 shares 10-Q · filed 2025-11-19 | |||
| 2023-12-31 | -4.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -4.04M shares derived: sum of 2 quarters · filed 2024-04-01 | 139.24K shares 10-K · filed 2024-04-01 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 4.18M shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 4.18M shares 10-Q · filed 2023-08-14 | |||
| 2020-12-31 | 40.00 shares 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 119.00 shares 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |